Cargando…
P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429398/ http://dx.doi.org/10.1097/01.HS9.0000969436.70152.b3 |
| _version_ | 1785090702994046976 |
|---|---|
| author | Shadman, Mazyar Y. Levy, Moshe Porter, Ryan M. Burke, John L. Cultrera, Jennifer Misleh, Jamal Sharman, Jeff F. Zafar, Syed By, Kunthel Cohen, Aileen Crescenzo, Rocco Idoine, Adam W. Flinn, Ian |
| author_facet | Shadman, Mazyar Y. Levy, Moshe Porter, Ryan M. Burke, John L. Cultrera, Jennifer Misleh, Jamal Sharman, Jeff F. Zafar, Syed By, Kunthel Cohen, Aileen Crescenzo, Rocco Idoine, Adam W. Flinn, Ian |
| author_sort | Shadman, Mazyar |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429398 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104293982023-08-17 P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB Shadman, Mazyar Y. Levy, Moshe Porter, Ryan M. Burke, John L. Cultrera, Jennifer Misleh, Jamal Sharman, Jeff F. Zafar, Syed By, Kunthel Cohen, Aileen Crescenzo, Rocco Idoine, Adam W. Flinn, Ian Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429398/ http://dx.doi.org/10.1097/01.HS9.0000969436.70152.b3 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Shadman, Mazyar Y. Levy, Moshe Porter, Ryan M. Burke, John L. Cultrera, Jennifer Misleh, Jamal Sharman, Jeff F. Zafar, Syed By, Kunthel Cohen, Aileen Crescenzo, Rocco Idoine, Adam W. Flinn, Ian P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB |
| title | P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB |
| title_full | P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB |
| title_fullStr | P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB |
| title_full_unstemmed | P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB |
| title_short | P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB |
| title_sort | p633: updated safety and efficacy results of zanubrutinib in patients with b-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429398/ http://dx.doi.org/10.1097/01.HS9.0000969436.70152.b3 |
| work_keys_str_mv | AT shadmanmazyar p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT ylevymoshe p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT porterryan p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT mburkejohn p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT lcultrerajennifer p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT mislehjamal p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT sharmanjeff p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT fzafarsyed p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT bykunthel p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT cohenaileen p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT crescenzorocco p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT idoineadam p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib AT wflinnian p633updatedsafetyandefficacyresultsofzanubrutinibinpatientswithbcellmalignancieswhoareintolerantofibrutinibandoracalabrutinib |